AstraZeneca

Open: 62.99 Close: 63.23 Change: 0.24

Are you still looking for information about AstraZeneca? An AI summarized it for you.

Are looking for the most relevant information about AstraZeneca? Investor spend a lot of time searching for information to make investment decisions in AstraZeneca. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, UK, company, vaccine, respiratory, major, hospital, and the most common words in the summary are: astrazeneca, vaccine, company, best, news, pharmaceutical, drug, . One of the sentences in the summary was: AstraZeneca PLC ADR closed $13.33 short of its 52-week high ($76.56) FDA accepted a …

Concept Map

Semantic Network

Stock Summary

AstraZeneca PLC focuses on the discovery, development, manufacture, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa,.

Today's Summary

AstraZeneca PLC ADR closed $13.33 short of its 52-week high ($76.56) FDA accepted a supplemental biologics license application for FluMist.

Today's News

A supply shortage means a drug that can prevent respiratory syncytial virus (RSV) in infants wont have a major immediate impact, childrens hospitals said. Childrens hospitals are preparing for a surge in admissions this respiratory disease season. AstraZeneca is leading the way in the way of organising data and information in the form of a graph. The company recently presented on the innovations to make data more accessible and insightful for internal biopharma research customers. AstraZeneca PLC ADR closed $13.33 short of its 52-week high ($76.56), which the company reached on April 25th. FDA accepted a supplemental biologics license application for FluMist, a nasal spray influenza vaccine. AstraZeneca is committed to making medicines available for the millions of people worldwide living with Cardiovascular, Renal and Metabolic (CVRM) diseases. It has been involved in developing the Oxford–AstraZeneca COVID-19 vaccine. AstraZeneca announced plans for a major corporate restructuring in March 2013. Company announced closure of research and development activities at Alderley Park in Cheshire and Loughborough in UK and at Lund in Sweden. AstraZeneca has its headquarters in Cambridge, United Kingdom, and main R&D centres are in Cambridge (UK), Gaithersburg (Maryland, US), Gothenburg (Sweden) and Warsaw (Poland) In August 2012, Pascal Soriot was named CEO. AstraZeneca agreed to pay £505 million to settle a UK tax dispute related to transfer mispricing. In 2010, AstraZecas agreed to £505 million to settle tax dispute. Conflicting commitments to the UK and the EU. AstraZeneca underwrites Cambridge-Sweden flights. AstraZeneca Inks $1.8B in Immuno-Oncology Deals as Q1 Profit Dips. Oxford vaccine researchers have found winning formula David McKinney leaves AstraZeneca after 5 extremely rewarding and thoroughly enjoyable years. He will always be grateful to his fantastic colleagues for their support and collaboration during his time at the company.

Stock Profile

"AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Andexxa/Ondexxya, Atacand, Atacand HCT, Atacand Plus, Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, Xigduo/Xigduo, and Zestril XR for cardiovascular, renal, and metabolism diseases; Accolate, Accoleit, Vanticon, Bevespi Aerosphere, Breztri Aerosphere, Bricanyl Respules and Turbuhaler, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Rhinocort, Saphnelo, Symbicort, and Tezspire for respiratory and immunology; and Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. Its marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Neurimmune AG to develop and commercialize NI006; and Personalis, Inc. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom."

Keywords

How much time have you spent trying to decide whether investing in AstraZeneca? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about AstraZeneca are: AstraZeneca, UK, company, vaccine, respiratory, major, hospital, and the most common words in the summary are: astrazeneca, vaccine, company, best, news, pharmaceutical, drug, . One of the sentences in the summary was: AstraZeneca PLC ADR closed $13.33 short of its 52-week high ($76.56) FDA accepted a supplemental biologics license application for FluMist.. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #astrazeneca #vaccine #company #best #news #pharmaceutical #drug.